{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:48:56Z","timestamp":1760143736490,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,7]],"date-time":"2020-12-07T00:00:00Z","timestamp":1607299200000},"content-version":"am","delay-in-days":372,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Presse M\u00e9dicale"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.lpm.2019.07.027","type":"journal-article","created":{"date-parts":[[2019,8,28]],"date-time":"2019-08-28T17:54:19Z","timestamp":1567014859000},"page":"1431-1438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["HTA essentielle r\u00e9sistante\u00a0: place de la spironolactone"],"prefix":"10.1016","volume":"48","author":[{"given":"Aur\u00e9lien","family":"Lorthioir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e8s","family":"Belmihoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fouassier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Amar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lpm.2019.07.027_bib0150","doi-asserted-by":"crossref","first-page":"e736","DOI":"10.1016\/S2214-109X(18)30259-6","article-title":"May Measurement Month 2017: an analysis of blood pressure screening results worldwide","volume":"6","author":"Beaney","year":"2018","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.lpm.2019.07.027_bib0155","first-page":"170","article-title":"L\u2019hypertension art\u00e9rielle en France\u00a0: pr\u00e9valence, traitement et contr\u00f4le en 2015\u00a0et \u00e9volutions depuis 2006","volume":"10","author":"Perrine","year":"2018","journal-title":"Bull Epidemiol Hebd"},{"key":"10.1016\/j.lpm.2019.07.027_bib0160","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.lpm.2014.07.016","article-title":"Management of resistant hypertension. Expert consensus statement from the French Society of Hypertension, an affiliate of the French Society of Cardiology","volume":"43","author":"Denolle","year":"2014","journal-title":"Presse Med"},{"key":"10.1016\/j.lpm.2019.07.027_bib0165","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension","volume":"39","author":"Williams","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lpm.2019.07.027_bib0170","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1161\/HYP.0000000000000084","article-title":"Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association","volume":"72","author":"Carey","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0175","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1016\/j.jacc.2012.08.1002","article-title":"Eligibility for renal denervation in patients with resistant hypertension: when enthusiasm meets reality in real-life patients","volume":"60","author":"Savard","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lpm.2019.07.027_bib0180","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/jhh.2013.140","article-title":"Apparent and true resistant hypertension: definition, prevalence and outcomes","volume":"28","author":"Judd","year":"2014","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.lpm.2019.07.027_bib0185","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","article-title":"Incidence and prognosis of resistant hypertension in hypertensive patients","volume":"125","author":"Daugherty","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2019.07.027_bib0190","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1161\/CIRCULATIONAHA.111.030189","article-title":"Uncontrolled and apparent treatment-resistant hypertension in the United States, 1988 to 2008","volume":"124","author":"Egan","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2019.07.027_bib0195","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/hr.2013.30","article-title":"Resistant hypertension and target organ damage","volume":"36","author":"Muiesan","year":"2013","journal-title":"Hypertens Res"},{"key":"10.1016\/j.lpm.2019.07.027_bib0200","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1161\/HYPERTENSIONAHA.111.179788","article-title":"Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension","volume":"58","author":"Pedrosa","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0205","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/HYPERTENSIONAHA.113.01448","article-title":"Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network","volume":"62","author":"Egan","year":"2013","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0210","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.jash.2016.03.186","article-title":"Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement","volume":"10","author":"Bhatt","year":"2016","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.lpm.2019.07.027_bib0215","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1161\/HYPERTENSIONAHA.114.05021","article-title":"Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects","volume":"65","author":"Roush","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0220","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1161\/HYPERTENSIONAHA.116.07464","article-title":"Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension","volume":"68","author":"Berra","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0225","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1161\/CIRCULATIONAHA.116.022922","article-title":"Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial","volume":"134","author":"Azizi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.lpm.2019.07.027_bib0230","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1161\/HYPERTENSIONAHA.116.08729","article-title":"Risk factors for nonadherence to antihypertensive treatment","volume":"69","author":"Gupta","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0235","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1161\/HYPERTENSIONAHA.109.131235","article-title":"Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial","volume":"54","author":"Pimenta","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0240","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-042711-135929","article-title":"Hyperaldosteronism as a common cause of resistant hypertension","volume":"64","author":"Calhoun","year":"2013","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.lpm.2019.07.027_bib0245","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1161\/HYPERTENSIONAHA.116.08751","article-title":"Case of primary aldosteronism with discordant hormonal and computed tomographic findings","volume":"69","author":"Amar","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0250","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1093\/ajh\/hpv031","article-title":"The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies","volume":"28","author":"Dahal","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.lpm.2019.07.027_bib0255","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","article-title":"Effect of spironolactone on blood pressure in subjects with resistant hypertension","volume":"49","author":"Chapman","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0260","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.169961","article-title":"Addition of spironolactone in patients with resistant arterial hypertension (ASPIRANT): a randomized, double-blind, placebo-controlled trial","volume":"57","author":"V\u00e1clav\u00edk","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0265","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.lpm.2019.07.027_bib0270","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","article-title":"Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension","volume":"31","author":"Colussi","year":"2013","journal-title":"J Hypertens"},{"key":"10.1016\/j.lpm.2019.07.027_bib0275","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/0002-9149(87)91030-7","article-title":"Efficacy and tolerance of spironolactone in essential hypertension","volume":"60","author":"Jeunemaitre","year":"1987","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.lpm.2019.07.027_bib0280","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S2213-8587(18)30071-8","article-title":"Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies","volume":"6","author":"Williams","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.lpm.2019.07.027_bib0285","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1161\/HYPERTENSIONAHA.117.10662","article-title":"Spironolactone versus clonidine as a fourth-drug therapy for resistant hypertension: the ReHOT Randomized Study (Resistant Hypertension Optimal Treatment)","volume":"71","author":"Krieger","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.lpm.2019.07.027_bib0145","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0b013e3283551e98","article-title":"Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study","volume":"30","author":"Bobrie","year":"2012","journal-title":"J Hypertens"}],"container-title":["La Presse M\u00e9dicale"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219303392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0755498219303392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:06:10Z","timestamp":1760105170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0755498219303392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":29,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["S0755498219303392"],"URL":"https:\/\/doi.org\/10.1016\/j.lpm.2019.07.027","relation":{},"ISSN":["0755-4982"],"issn-type":[{"type":"print","value":"0755-4982"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HTA essentielle r\u00e9sistante\u00a0: place de la spironolactone","name":"articletitle","label":"Article Title"},{"value":"La Presse M\u00e9dicale","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lpm.2019.07.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}